Biogen's Spinraza Sales Plateau; The Challenge Is Keeping Up With The Successful Launch

Sales of Biogen's blockbuster rare disease drug moderated in the first quarter as the company worked through the bolus of urgent infant and pediatric patients awaiting treatment in the US.